Cognitive Therapy for PTSD in Addiction Treatment

This study is currently recruiting participants.

Verified by National Institute on Drug Abuse (NIDA), May 2008

First Received: May 23, 2008 No Changes Posted

Sponsored by:	National Institute on Drug Abuse (NIDA)
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00685451

Purpose

The purpose of this phase of the study is to assess the feasibility of a cognitive behavioral therapy for post-traumatic stress disorder (PTSD) in persons receiving outpatient services at an addiction treatment program. The next phase of the study will be a more rigorous investigation of the efficacy of the PTSD therapy within addiction treatment settings.

Condition	Intervention	Phase
Stress Disorders, Post Traumatic Substance-Related Disorders	Behavioral: Cognitive Behavioral Therapy (CBT)	Phase I Phase II

MedlinePlus related topics: Post-Traumatic Stress Disorder

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	Cognitive Therapy for PTSD in Addiction Treatment

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

decrease in substance use at post-therapy and 3 month follow-up
reduction in PTSD symptoms at post-therapy and 3 month follow-up
improvement in addiction treatment retention

Secondary Outcome Measures:

examine impact of depression, anxiety, and borderline personality disorder on outcomes
explore impact of motivation and treatment readiness on outcomes
assess overall level of satisfaction with treatment on outcomes
examine impact of other services received on outcomes

Estimated Enrollment:	100
Study Start Date:	July 2002

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

At least 18 years old;
Actively enrolled in intensive outpatient addiction services;
Diagnosis of PTSD; and
Willing and able to provide informed consent.

Exclusion Criteria:

Acute psychotic disorder;
Psychiatric hospitalization or suicide attempt in the past 2 months;
Known impending court appearance or legal circumstance that may result in incarceration within next 8 months; and
Known medical condition that would likely cause study withdrawal in the next 8 months.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00685451

Contacts

Contact: Stephanie C. Acquilano, M.A.

603-271-5747

stephanie.acquilano@dartmouth.edu

Locations

United States, New Hampshire
Fresh Start at Concord Hospital	Recruiting
Concord, New Hampshire, United States, 03301
Farnum Center	Recruiting
Manchester, New Hampshire, United States, 03104
United States, Vermont
Quitting Time	Recruiting
Wilder, Vermont, United States, 05088

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Investigators

Principal Investigator:

Mark P. McGovern, Ph.D.

Dartmouth-Hitchcock Medical Center

More Information

No publications provided

Study ID Numbers:	5K23DA016574
Study First Received:	May 23, 2008
Last Updated:	May 23, 2008
ClinicalTrials.gov Identifier:	NCT00685451 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by National Institute on Drug Abuse (NIDA):

cognitive behavior therapy
addiction
PTSD

Study placed in the following topic categories:

Behavior, Addictive
Anxiety Disorders
Mental Disorders
Substance-Related Disorders

Disorders of Environmental Origin
Stress Disorders, Post-Traumatic
Stress
Stress Disorders, Traumatic

Additional relevant MeSH terms:

Pathologic Processes
Disease
Anxiety Disorders
Mental Disorders

Substance-Related Disorders
Disorders of Environmental Origin
Stress Disorders, Post-Traumatic
Stress Disorders, Traumatic

ClinicalTrials.gov processed this record on May 07, 2009